To observe the clinical efficacy of Modified Erchen Decoction（二陈汤加减）in the treatment of nonalcoholic fatty liver disease，and analyze the impact of this treatment on liver function，blood lipids and other indicators in patients.

The clinical data of 80 patients with non-alcoholic fatty liver disease admitted to Dongguan Hospital of Guangzhou University of Chinese Medicine from January 2022 to June 2023 were collected. They were randomly divided into a control group and an observation group，with 40 patients in each group. The patients of the control group were treated with Atorvastatin Calcium Tablets. Those of the observation group were treated with Modified Erchen Decoction on the basis of the control group. The clinical efficacy，liver function，blood lipid levels and changes in inflammatory markers were observed and compared between the two groups.

The effective rate of the control group was 75.00%（30/40），while that of the observation group was 92.50%（37/40）. Compared with that of the control group，the effective rate of the observation group significantly increased，with a statistically significant difference（P<0.05）. After treatment，the levels of aspartate aminotransferase（AST），alanine aminotransferase（ALT）and total bilirubin in serum（TBIL）in the observation group significantly decreased compared to those in the control group（P<0.01）. There was no significant difference in values of controlled attenuation parameter（cap）or body mass index（BMI）between the two groups before administration（P>0.05）. After the intervention，the values of CAPand BMI of the observation group significantly decreased compared to those of the control group（P<0.01）. There was no significant difference in blood lipid levels between the two groups before administration（P>0.05）. After intervention，compared to those of the control group，the levels of triglycerides（TG），low density lipoprotein cholesterol（LDL-C）and total cholesterol（TC）of the observation group patients were significantly reduced，while the high density lipoprotein cholesterol（HDL-C）levels were significantly upregulated，with statistically significant differences（P<0.05，P<0.01）. There was no significant difference in the levels of inflammatory indicators between the two groups before administration（P>0.05）. After intervention，compared to those of the control group，the levels of IL-6，tumor necrosis factor-α（TNF-α）and hypersensitive C-reactive protein（hs-CRP）in the observation group were significantly decreased than those in the control group（P<0.05）. There were 4 cases of adverse reactions in the control group，with an incidence rate of 10.00%（4/40），and 3 cases in the observation group，with an incidence rate of 7.50%（3/40）. There was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）.

The combination of Modified Erchen Decoction and conventional Western medicine treatment can not only improve the clinical efficacy of NAFLD，improve liver function，reduce blood lipid levels，but also delay the process of liver fibrosis，inhibit the level of inflammation in the body，and improve the patients'condition without increasing adverse reactions.